Highlights Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 09:00:12 05/06/2026 pm IST			5-day change	1st Jan Change
485.60 ^CHF	-1.18%		-2.96%	-9.71%

04/06	Intron Health Downgrades Lonza Group to Sell, Cuts PT	MT
12/05	Swiss stocks - Factors to watch on May 12	RE

Highlights

12/05	For final dividend	FA
12/05		FA
12/05	For final dividend	FA
12/05	Capital return instalment	FA
08/05	Lonza Group AG Approves Dividend, Payable from May 15, 2026	CI
08/05	Lonza Group: Q1 commentary in line; 2026 guidance reaffirmed
08/05	European Commission OKs Acquisition of Lonza Division by Lone Star Funds	MT
08/05	Lonza Says Big Pharma Might Delay Outsourcing Decisions Amid U.S. Investments	DJ
08/05	Lonza Group Maintains FY26 Sales Growth Guidance	MT
08/05	Lonza Group Delivers Strong Performance in Q1	MT
08/05	Lonza confirms FY outlook 2026	RE
01/05	Microsize, Inc. and Schedio SA completed the acquisition of Micro-Macinazione S.A. from Lonza Group AG.	CI
27/04	RBC Expects 'Uneventful' Lonza Q1 Update; Outperform Maintained	MT
21/04	Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug Products	CI
15/04	Berenberg: Lonza Group's Recent Subdued Valuation 'Good Entry Point'; Estimates Adjusted	MT
14/04	Lonza Group AG Proposes Final Cash Dividend, Payable on May 15, 2026	CI
25/03	STARLIMS Corporation agreed to acquire MODA Platform from Lonza Group AG	CI
09/03	Lonza Extends Long-term Production Tie-up for Genetix's Gene Therapy	MT
09/03	Lonza Seeks M&A	CI
09/03	Lonza to Become Pure-play Pharma Contract Developer With CHF2.3 Billion Sale of Capsules, Ingredients Division	MT
09/03	Lonza Agrees CHF2.3 Billion Sale of Capsules, Ingredients Business to Conclude Transformation Plan	MT
07/03	Lone Star Fund XII, L.P., a fund managed by Lone Star Americas Acquisitions, Inc. entered into an agreement to acquire 60% stake in Capsules & Health Ingredients business of Lonza Group AG from Lonza Group AG for CHF 1.7 billion.	CI
06/03	Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal	DJ
06/03	Lonza to sell capsule and health ingredients business to Lone Star for $3.0 billion	RE
04/03	Octane Biotech Inc. agreed to acquire Personalized Medicine business from Lonza Group AG.	CI